Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 + SI-B003 in NSCLC and nasopharyngeal carcinoma
NCT05956587Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC), nasopharyngeal carcinoma (NPC), sponsored by Biokin Pharmaceutical. Started Jan 2024; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05956587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05956587.